ZYMEWORKS
LIVE

Serial Number

79412060

Owner

Zymeworks BC Inc.

Attorney

Kiranjit K Dharsan

Filing Date

Oct 15, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ZYMEWORKS Trademark

Serial Number: 79412060

ZYMEWORKS is a trademark filed by Zymeworks BC Inc. on October 15, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently pending registration.

Owner Contact Info

Zymeworks BC Inc. (11 trademarks)

Suite 800 - 114 East 4th Avenue

Entity Type: 03

Trademark Details

Filing Date

October 15, 2024

Registration Date

Not Registered

Goods & Services

Chemical, biochemical and biological research and analysis; research and development in the field of biotechnology; medical and pharmacological research services and product development in the field of biologics, proteomics, and antibody engineering; pharmaceutical products development and pharmaceutical product evaluation; scientific research in the nature of conducting clinical trials for others for pharmaceutical products; scientific research and development of preparations, agents and technology for the development of antibody therapeutics for the treatment, and prophylaxis of human diseases, disorders and conditions, namely, cancer, auto immune and inflammatory diseases; providing scientific information to scientists, physicians and health care providers in the fields of cancer, auto immune diseases, inflammatory diseases, and infectious diseases; chemical molecular analysis provided to pharmaceutical, biotechnology and chemical industries using proprietary software and proprietary analytical tools and algorithms; product optimization services, namely, research and development services of new pharmaceutical products provided to pharmaceutical, biotechnology and chemical industries using proprietary software and proprietary analytical tools and algorithms

Pharmaceutical preparations for regulating the immune system, antibodies, antibody-drug conjugates, and their constituents; medicines for human purposes for the treatment of cancer, autoimmune and autoinflammatory diseases; diagnostic preparations for medical purposes; chemical preparations for pharmaceutical and medical purposes, namely, the treatment and diagnosis of cancer, autoimmune and autoinflammatory diseases; chemical preparations for pharmaceutical and medical purposes, namely, regulating the immune system, antibodies, antibody-drug conjugates, and their constituents; biological preparations for medical and pharmaceutical purposes, namely, biologic and recombinant therapeutic agents comprised of monoclonal antibodies, multispecific and bispecific antibodies, antibody fragments, antibody-drug conjugates, fusion proteins, recombinant proteins, cytokines, peptides, and nucleic acid-based biologics and their constituents, derivatives, variants, conjugates, and formulations; therapeutic preparations, prophylactic preparations, and pharmaceutical products and agents for the treatment or prophylaxis of cancer; therapeutic preparations, prophylactic preparations, and pharmaceutical products and agents for the treatment or prophylaxis of human autoimmune diseases, disorders and conditions; therapeutic preparations, prophylactic preparations, and pharmaceutical products and agents for the treatment or prophylaxis of human inflammatory diseases, disorders and conditions

Intellectual property licensing services

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 2, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 2, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 2, 2025 TROA
REFUSAL PROCESSED BY IB
Jun 21, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 3, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jun 3, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 1, 2025 RFCR
NON-FINAL ACTION WRITTEN
Mar 31, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 24, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Dec 13, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 13, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 12, 2024 REPR